Could this Stem-Cell infusion end insulin shots for diabetics with kidney transplants?
NCT ID NCT06832410
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 study tests VX-880, a stem-cell therapy infused into the liver, in 10 people with type 1 diabetes who have already received a kidney transplant. The main goal is to see if participants can stop using insulin entirely. The therapy is given alongside standard transplant drugs to prevent rejection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VX-880 (Zimislecel), a stem-cell derived therapy infused into the liver's portal vein
What this could lead to
If successful, this could allow people with type 1 diabetes and a kidney transplant to stop taking insulin, while continuing their transplant-related immunosuppression.
What could go wrong
This is a very small early-phase 3 trial (only 10 participants). The therapy requires lifelong immunosuppression for the kidney transplant, and it may not achieve lasting insulin independence or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
King Abdullah International Medical Research Center (KAIMRC) - Riyadh - Endocrinology
RECRUITINGRiyadh, Saudi Arabia
-
King Faisal Specialist Hospital & Research Centre - Riyadh - Endocrinology
RECRUITINGRiyadh, Saudi Arabia
-
Montefiore Clinical and Translational Research Center - Endocrinology
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
-
Perelman Center for Advanced Medicine - Endocrinology
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Toronto General Hospital - Endocrinology
RECRUITINGToronto, Canada
-
UW University Hospital - Endocrinology
RECRUITINGMadison, Wisconsin, 53792, United States
-
Vancouver General Hospital - Gordon and Leslie Diamond Health Care Centre
RECRUITINGVancouver, Canada